Tuesday, September 18, 2018 -- First results from a clinical trial of a procedure to open obstructed airways in patients with chronic obstructive pulmonary disease have shown that it significantly reduces problems associated with the disease and is safe.
Monday, September 17, 2018 -- AstraZeneca has unveiled late-stage data backing use of its triple combination therapy PT010 in patients with chronic obstructive pulmonary disease (COPD).
Tuesday, September 18, 2018 -- Pooled data from two identical 12-week pivotal Phase 3 trials (N=1229) in patients with moderate to very severe COPD showed that the mean annualized rate of all COPD exacerbations was 0.47, 0.45, and 0.55 for revefenacin 175mcg/day, 88mcg/day, and placebo, respectively.
Tuesday, September 18, 2018 -- AstraZeneca struck out in May in trying to expand severe eosinophilic asthma drug Fasenra into COPD. But it does have new long-term data that could bolster the drug in its current indication.
Monday, September 17, 2018 -- (MedPage Today) -- And models show exacerbations further decreasing
Tuesday, September 18, 2018 -- (MedPage Today) -- Tested as standalone, but potential role seen as add-on therapy
Wednesday, September 19, 2018 -- (MedPage Today) -- One-time therapy showed most benefit in highly symptomatic patients
Sunday, September 16, 2018 -- BGF MDI was efficacious, well tolerated, and could be a more appropriate treatment than the corresponding dual therapies for symptomatic patients with moderate to very severe COPD, irrespective of exacerbation history.